

Lumito and Navinci initiate pilot project – promising initial results from evaluation of combined technology

Lumito AB (publ) ("Lumito" or the "Company") today announces that the Company has initiated a pilot project together with the Swedish biotech company Navinci Diagnostics AB ("Navinci") to evaluate the possibilities of combining the companies' respective technologies within advanced tissue analysis.

The pilot project aims to combine Lumito's high-sensitivity image analysis platform with Navinci's *in situ* Proximity Ligation Technology (isPLA). By combining the strengths of both technologies, the ambition is to enable more sensitive and information-rich analyses of tissue samples, providing researchers with deeper biological insights.

Navinci's *in situ* Proximity Ligation Assay (isPLA) technology enables highly specific detection and quantification of proteins, protein-protein interactions, and post-translational modifications directly in tissue samples while preserving their spatial context. The technology is widely applicable in fields such as cancer research, translational research, biomarker discovery, and drug development, where understanding cellular signaling pathways and molecular interactions is critical.

As a first step in the pilot project, Navinci has combined Lumito's SCIZYS Erbium kit together with its Naveni® isPLA technology, after which the samples were sent to Lumito for scanning in the company's SCIZYS scanner. The initial results have been jointly evaluated and are considered very promising, with high image quality. Work is now continuing with planning of the next steps. The collaboration is well aligned with Lumito's strategy to establish partnerships with players in tissue analysis to develop new applications, create customer value, and strengthen the Company's commercial position.

"We are very positive about the initial results. The combination of Lumito's sensitive detection platform and Navinci's established technology for precise detection of proteins and protein-protein interactions has the potential to create a powerful tool for researchers seeking to extract more information from complex biological samples. It is still an early-stage project, but the initial results give us good reason to continue the evaluation", says Sanna Wallenborg, CEO of Lumito.

"We want Navinci's technology to work seamlessly with different imaging platforms, so it's very encouraging to see how well it performs together with Lumito's scanner. Navinci's platform allows researchers to study proteins and protein interactions directly in their tissue context, and Lumito's imaging technology adds impressive sensitivity and image quality. Seeing how easily the two technologies come together – and the quality of the results – reinforces the potential to support researchers in biomarker discovery and translational studies", says Jenny Sundqvist, CEO of Navinci.

The companies will inform the market about the continued development of the pilot project as further results or commercially relevant milestones are achieved.

About Navinci

Navinci is a Swedish biotech company specialising in developing innovative solutions for studying in situ protein expression and interactions. With a focus and a strong legacy in developing in situ proximity ligation assay technology, Navinci has established itself as a center of excellence in the field and has a broad portfolio of products that help researchers study protein interactions in depth.

For further information, please contact:

Sanna Wallenborg, CEO Lumito

E-mail: sw@lumito.se

Ph: +4670-870 01 68

About Lumito

Lumito specialises in medical technology and translational research in digital tissue imaging. Lumito offers a groundbreaking, highly sensitive imaging technique to locate and measure protein biomarkers in tissue samples using up-converting nanoparticles (UCNPs) through its patented research platform. The technology combines image data with precise biomarker detection, enabling images with higher contrast where irrelevant background information is filtered out. The technique can enhance the analysis of tissue samples by increasing objectivity, thereby contributing to research for more quantifiable diagnoses and optimised treatments. Lumito primarily focuses on drug development and digital pathology and is a spin-off from a research group at Lund University's Department of Atomic Physics and Laser Center. www.lumito.se/en/

The share is traded on NGM Growth Market under the name LUMITO, and Mentor is Mangold Fondkommission.

Attachments

[Lumito and Navinci initiate pilot project – promising initial results from evaluation of combined technology](#)